"Finding NEMO" in NRAS-mutant melanoma: a step towards a sequential strategy?

Affiliations

¹ University Hospital of Parma, Medical Oncology Unit, Via Gramsci 14, 43126, Parma, Italy.
² University Hospital of Parma, Medical Oncology Unit, Via Gramsci 14, 43126, Parma, Italy. Electronic address: sebabuti@libero.it.

Comment

Melissa Bersanelli et al. Lancet Oncol. 2017 Jun.

. 2017 Jun;18(6):e298.

doi: 10.1016/S1470-2045(17)30349-2.

¹ University Hospital of Parma, Medical Oncology Unit, Via Gramsci 14, 43126, Parma, Italy.
² University Hospital of Parma, Medical Oncology Unit, Via Gramsci 14, 43126, Parma, Italy. Electronic address: sebabuti@libero.it.

No abstract available

Comment on

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.
Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Bozón V, Long GV, Flaherty K. Dummer R, et al. Lancet Oncol. 2017 Apr;18(4):435-445. doi: 10.1016/S1470-2045(17)30180-8. Epub 2017 Mar 9. Lancet Oncol. 2017. PMID: 28284557 Clinical Trial.